Karkinos Healthcare, a step-down subsidiary of reliance industries , has completed HPV DNA screening for over one lakh women across India, marking a milestone in expanding access to cervical cancer screening. This achievement strengthens India's cervical cancer prevention efforts by addressing challenges related to access and loss to follow-up after a positive result. The company utilizes a digitally enabled continuum of care that integrates awareness, screening, tracking, triage, navigation, and follow-up to ensure women remain connected to care from screening to treatment.

The screening program employs World Health Organization-recommended HPV DNA testing, which is cited as a more reliable primary screen than visual inspection or cytology. Dr Neerja Bhatla, Consultant at Karkinos Healthcare, emphasized that ensuring linkage to diagnosis and treatment is as critical as testing at scale. The program targets women in districts and small towns, aiming to bridge the gap in reach and public health gains.

Karkinos Healthcare implemented this milestone through diverse models, including public-health programmes, public-private partnerships, and CSR-supported initiatives. A significant portion of the women reached belong to underserved or high-risk communities who may otherwise lack access to screening. The company stated that the learnings and infrastructure developed can support wider adoption of organized cervical cancer screening.

The company has dedicated this milestone to the late Dr R. Sankaranarayanan, acknowledging his scientific leadership in early detection. Karkinos Healthcare expressed confidence in scaling the journey to one million tests next, backed by the support of Reliance. The program also acknowledges guidance from Dr Partha Basu of the International Agency for Research on Cancer (IARC).

Key Milestone Details

About Karkinos Healthcare

Karkinos Healthcare Pvt. Ltd. is a technology-led oncology platform enabling discovery through care delivery. It operates a Distributed Cancer Care Model using a hub-and-spoke approach to address cancer prevention, early detection, diagnostics, and care delivery. The company collaborates with leading academic and healthcare institutions to deliver quality cancer care.

Reliance Industries has attracted bullish coverage from three major global brokerages — CLSA, Nomura, and Jefferies — all maintaining positive ratings on the stock. The brokerages collectively cite artificial intelligence initiatives, new energy commissioning, Jio IPO progress, and FMCG monetisation as key catalysts expected to drive a meaningful rerating of the stock.

Brokerage Ratings and Target Prices

All three brokerages have issued Buy or equivalent ratings on Reliance Industries, with target prices ranging from ₹1,640 to ₹1,800. The following table summarises their current stances:

New Energy Businesses as Key Growth Catalysts

CLSA has identified Reliance Industries' new energy vertical as a significant driver of medium-term rerating potential. The brokerage cited a broad range of initiatives underpinning this outlook, spanning manufacturing scale-up, technology investments, and emerging clean energy segments. Jefferies similarly flagged new energy monetisation as a core rerating lever, while Nomura highlighted new energy commissioning as a forward growth driver.

These developments, according to CLSA, collectively position Reliance Industries for a meaningful rerating as execution progresses across these high-potential verticals.

AI, Jio IPO, and Digital Growth

Artificial intelligence has emerged as a prominent theme across all three brokerage reports. CLSA specifically highlighted AI initiatives as a source of significant value not yet reflected in current valuations, while Jefferies pointed to AI as a key rerating catalyst alongside FMCG growth. Nomura's thesis centres on sovereign AI and Jio IPO progress as forward catalysts, underscoring the strategic importance of Reliance's digital and telecom businesses in driving long-term shareholder value.

FCF Growth Amid OPCF Decline

CLSA noted that free cash flow growth was primarily driven by lower capital expenditure, even as operating profit cash flow recorded a 3% year-on-year decline. This dynamic underscores a shift in the company's capital allocation approach, where reduced capex spending has supported cash generation despite softer operational cash flow performance.

Key AGM Catalysts Identified

CLSA has highlighted several themes as potential catalysts at the upcoming Annual General Meeting (AGM). These areas are expected to draw significant investor attention and could serve as key narratives for the company's strategic direction:

• AI and data centres — expansion into artificial intelligence infrastructure and data centre capabilities
• Media and consumer expansion — growth initiatives across the company's media and consumer-facing businesses
• New energy businesses — progress and updates on the company's renewable and new energy ventures
• Value-unlocking plans — potential announcements related to restructuring, listings, or other value-unlocking strategies

Cost Pressures and Operating Leverage Concerns

Despite the positive ratings and identified growth catalysts, CLSA flagged certain financial concerns that could temper operating leverage going forward. Specifically, high operating expenditure and interest-cost capitalisation were cited as factors that may weigh on the company's ability to translate revenue growth into proportionate improvements in operating profitability. These elements represent areas of scrutiny for investors monitoring the company's margin trajectory.